Integumen PLC Trading update and Board changes (6239Z)

TIDMSKIN

RNS Number : 6239Z

Integumen PLC

21 May 2019

AIM share code: SKIN

21 May 2019

Integumen PLC

("Integumen" or "Company")

Trading Update and Board Changes

Integumen announces the resignation of Tony Richardson as Chairman and a director of the Company and Ross Andrews has been appointed as Chairman, with immediate effect. The Company expects to announce an additional non-executive director to the Board in due course.

In addition, the following trading update is based on unaudited management accounts for the year ended 31 December 2018. The Company has delivered a strong financial performance for the year, with revenues ahead of previous expectations:

   --      FY 2018 total revenue GBP502k increased 111% (FY 2017 : GBP238k); 

-- FY 2018 revenue from continued operations GBP274k increased 294% (FY 2017 : GBP93k) following Labskin test kit sales move to full skin-care product test services;

-- FY 2018 EBITDA losses reduced by 12% to (GBP1.25m) (FY 2017: (GBP1.40m)) cost savings achieved under new management in the last 4 months of 2018;

   --      Disposal of TSPro GmbH saving GBP1.19m in current and future liabilities; 
   --      Stoer For Men skin care range at monthly break-even by year-end 2018. 

Post Year-End 2018 Events

-- Transformational GBP3m all-share Acquisition of Rinocloud Limited enabling scale-up of the business as it moves from a physical laboratory to an automated, real-time, real-world digital data platform;

   --      Successful fundraising of GBP2.75m (total); of which, 

o GBP232k was Vendor sale to allow 100% of Rinocloud to be acquired;

   --      Additional strategic reduction of the indebtedness of the business: 

o Disposal of Visible Youth Group - saving GBP245k of future contractual liabilities;

o Debt conversions - Venn GBP421k carried over since April 2017 IPO;

o Cellulac debt conversion - GBP400k for hi-tech laboratory equipment;

o Litigation issues settled - saving GBP250k of future liabilities.

Publication of Accounts

Integumen's Final Results and Annual Report will be published in June 2019,

Gerard Brandon - CEO of Integumen plc, comments:

"It is with regret that the board has accepted the resignation of Tony Richardson as Chairman and director of the Company. Tony, as CEO of Venn Life Sciences, had the foresight to identify the potential of Labskin as early as 2014, when it was acquired by Venn and has nurtured it from an early stage technology company, through a spin-out and IPO in 2017. As Chairman of Integumen, he was instrumental in securing funding and recently oversaw management changes that has moved Integumen into the clinical trials sector. His resignation removes any competitive conflict of interest with Venn.

Integumen continues its strong momentum well into 2019. With a more focused business, and in line with our strategy, we have now been able to demonstrate our ability to grow, both organically and through the successful post year-end transactions. Our digital and physical team members, across all subsidiaries, continue to deliver consistent reliable revenue growth as we scale-up our new digital platform."

Contacts

 
 Integumen plc              Gerard Brandon, CEO    [phone] 
 SPARK Advisory Partners 
  Limited                   Neil Baldwin/Andrew 
  (Nominated Adviser)        Emmott                [phone] 
                           ---------------------  --------------------- 
 Turner Pope Investments 
  (TPI) Limited (Broker)    Andy Thacker           [phone] 
                           ---------------------  --------------------- 
 

About Integumen:

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCKBLFLKEFXBBE

(END) Dow Jones Newswires

May 21, 2019 02:01 ET (06:01 GMT)